JP2025507416A - 解剖学的及び機能的な網膜萎縮の治療 - Google Patents

解剖学的及び機能的な網膜萎縮の治療 Download PDF

Info

Publication number
JP2025507416A
JP2025507416A JP2024548656A JP2024548656A JP2025507416A JP 2025507416 A JP2025507416 A JP 2025507416A JP 2024548656 A JP2024548656 A JP 2024548656A JP 2024548656 A JP2024548656 A JP 2024548656A JP 2025507416 A JP2025507416 A JP 2025507416A
Authority
JP
Japan
Prior art keywords
pharma
retinal
eye
disease
therapeutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507416A5 (enExample
Inventor
レズリー ペンフォールド フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Co Pty Ltd
Original Assignee
Eye Co Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022900318A external-priority patent/AU2022900318A0/en
Application filed by Eye Co Pty Ltd filed Critical Eye Co Pty Ltd
Publication of JP2025507416A publication Critical patent/JP2025507416A/ja
Publication of JP2025507416A5 publication Critical patent/JP2025507416A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024548656A 2022-02-15 2023-02-15 解剖学的及び機能的な網膜萎縮の治療 Pending JP2025507416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2022900318A AU2022900318A0 (en) 2022-02-15 Treatment of anti-vegf refractory ophthalmic retinal eye conditions
AU2022900318 2022-02-15
PCT/AU2023/050103 WO2023154980A1 (en) 2022-02-15 2023-02-15 Treatment of anatomical and functional retinal atrophies

Publications (2)

Publication Number Publication Date
JP2025507416A true JP2025507416A (ja) 2025-03-18
JP2025507416A5 JP2025507416A5 (enExample) 2026-02-24

Family

ID=87577221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548656A Pending JP2025507416A (ja) 2022-02-15 2023-02-15 解剖学的及び機能的な網膜萎縮の治療

Country Status (6)

Country Link
US (1) US20250387410A1 (enExample)
EP (1) EP4479061A4 (enExample)
JP (1) JP2025507416A (enExample)
CN (1) CN119031918A (enExample)
AU (1) AU2023221950A1 (enExample)
WO (1) WO2023154980A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019207515B2 (en) * 2018-01-10 2024-11-14 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
PL3684370T3 (pl) * 2018-02-26 2025-07-28 Eye Co Pty Ltd. Kompozycja i leczenie zaniku geograficznego fludrokortyzonem

Also Published As

Publication number Publication date
CN119031918A (zh) 2024-11-26
AU2023221950A1 (en) 2024-09-19
EP4479061A4 (en) 2026-01-07
WO2023154980A1 (en) 2023-08-24
US20250387410A1 (en) 2025-12-25
EP4479061A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
Arevalo et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months
Souied et al. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study
EP3441069B1 (en) Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
JP2025069279A (ja) 血管形成眼障害を処置するためのvegfアンタゴニストの使用
Arevalo et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
Mayer et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome
Verma et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema
CN115697333A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
CN110114066B (zh) 含沙丁胺醇的眼科药物
US20220331345A1 (en) Methods of Treating Retinal Vasculopathies
Mirshahi et al. Efficacy of adjuvant topical timolol–dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study
Pizzimenti et al. Central serous chorioretinopathy after epidural steroid injection
Nghiem-Buffet et al. Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
JP2025507416A (ja) 解剖学的及び機能的な網膜萎縮の治療
Singh et al. Cho
Krasniqi et al. Anti–VEGF Treatment in Macular Edema Due to Retinal Vein Occlusion
Senturk et al. Retinal sensitivity improvement after intravitreal triamcinolone acetonide injection for macular edema secondary to branch retinal vein occlusion
Hong et al. Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy
Kasetty et al. Complications, compliance, and 3-year outcomes after endolaserless vitrectomy with aflibercept monotherapy for proliferative diabetic retinopathy-related vitreous hemorrhage
US20250025452A1 (en) Compositions comprising axitinib and methods of treating ocular disorders
Pacella Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant: description of three case
Chan et al. Intraocular pressure changes after repeated intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration with or without glaucoma
Ahmad et al. Comparison of intravitreal Diclofenac-Sodium Versus intravitreal Triamcinolone in diabetic Macular Edema

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260213